FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149286249> ?p ?o ?g. }

• W2149286249 endingPage "1223" @default.
• W2149286249 startingPage "1216" @default.
• W2149286249 abstract "Abstract Purpose: In preclinical models, calcitriol and the tyrosine kinase inhibitor gefitinib are synergistic and modulate extracellular signal-regulated kinase (Erk) and Akt pathways. Therefore, we conducted a phase I study of calcitriol and gefitinib to determine the maximum tolerated dose (MTD) of this combination. Experimental Design: Calcitriol was given i.v. over 1 h on weeks 1, 3, and weekly thereafter. Gefitinib was given at a fixed oral daily dose of 250 mg starting at week 2 (day 8). Escalation occurred in cohorts of three patients until the MTD was defined. Pharmacokinetic studies were done for calcitriol and gefitinib. Serial skin biopsies were done to investigate epidermal growth factor receptor (EGFR) pathway pharmacodynamic interactions. Results: Thirty-two patients were treated. Dose-limiting hypercalcemia was noted in two of four patients receiving 96 μg/wk of calcitriol. One of seven patients developed dose-limiting hypercalcemia at the MTD 74 μg/wk calcitriol dose level. The relationship between calcitriol dose and peak serum calcitriol (Cmax) and systemic exposure (AUC) was linear. Mean (±SD) serum calcitriol Cmax at the MTD was 6.68 ± 1.42 ng/mL. Gefitinib treatment inhibited EGFR, Akt, and Erk phosphorylation in the skin. Calcitriol did not have consistent effects on skin EGFR or its downstream elements. The combination of gefitinib and calcitriol did not modulate tumor EGFR pathway in patients with serial tumor biopsies. Conclusions: High doses of weekly i.v. calcitriol can be administered safely in combination with gefitinib. Calcitriol concentrations achieved at the MTD 74 μg calcitriol exceed in vivo concentrations associated with antitumor activity in preclinical models." @default.
• W2149286249 created "2016-06-24" @default.
• W2149286249 creator A5000500580 @default.
• W2149286249 creator A5012581623 @default.
• W2149286249 creator A5018099630 @default.
• W2149286249 creator A5018677580 @default.
• W2149286249 creator A5025109344 @default.
• W2149286249 creator A5028257767 @default.
• W2149286249 creator A5041348263 @default.
• W2149286249 creator A5065161783 @default.
• W2149286249 creator A5069146590 @default.
• W2149286249 creator A5081220639 @default.
• W2149286249 creator A5086231738 @default.
• W2149286249 date "2007-02-15" @default.
• W2149286249 modified "2023-10-16" @default.
• W2149286249 title "A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors" @default.
• W2149286249 cites W1480405375 @default.
• W2149286249 cites W1975217765 @default.
• W2149286249 cites W1986527803 @default.
• W2149286249 cites W2005441877 @default.
• W2149286249 cites W2005718411 @default.
• W2149286249 cites W2020810936 @default.
• W2149286249 cites W2028798103 @default.
• W2149286249 cites W2040684042 @default.
• W2149286249 cites W2045993433 @default.
• W2149286249 cites W2049389638 @default.
• W2149286249 cites W2059937375 @default.
• W2149286249 cites W2061976862 @default.
• W2149286249 cites W2078919601 @default.
• W2149286249 cites W2126314379 @default.
• W2149286249 cites W2127800995 @default.
• W2149286249 cites W2128873194 @default.
• W2149286249 cites W2139248078 @default.
• W2149286249 cites W2146404049 @default.
• W2149286249 cites W2160180902 @default.
• W2149286249 cites W2167132436 @default.
• W2149286249 cites W2274103071 @default.
• W2149286249 cites W2403795152 @default.
• W2149286249 cites W4238161713 @default.
• W2149286249 cites W4240064739 @default.
• W2149286249 cites W4323874020 @default.
• W2149286249 doi "https://doi.org/10.1158/1078-0432.ccr-06-1165" @default.
• W2149286249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17317832" @default.
• W2149286249 hasPublicationYear "2007" @default.
• W2149286249 type Work @default.
• W2149286249 sameAs 2149286249 @default.
• W2149286249 citedByCount "80" @default.
• W2149286249 countsByYear W21492862492012 @default.
• W2149286249 countsByYear W21492862492013 @default.
• W2149286249 countsByYear W21492862492014 @default.
• W2149286249 countsByYear W21492862492015 @default.
• W2149286249 countsByYear W21492862492016 @default.
• W2149286249 countsByYear W21492862492017 @default.
• W2149286249 countsByYear W21492862492018 @default.
• W2149286249 countsByYear W21492862492020 @default.
• W2149286249 countsByYear W21492862492021 @default.
• W2149286249 countsByYear W21492862492022 @default.
• W2149286249 countsByYear W21492862492023 @default.
• W2149286249 crossrefType "journal-article" @default.
• W2149286249 hasAuthorship W2149286249A5000500580 @default.
• W2149286249 hasAuthorship W2149286249A5012581623 @default.
• W2149286249 hasAuthorship W2149286249A5018099630 @default.
• W2149286249 hasAuthorship W2149286249A5018677580 @default.
• W2149286249 hasAuthorship W2149286249A5025109344 @default.
• W2149286249 hasAuthorship W2149286249A5028257767 @default.
• W2149286249 hasAuthorship W2149286249A5041348263 @default.
• W2149286249 hasAuthorship W2149286249A5065161783 @default.
• W2149286249 hasAuthorship W2149286249A5069146590 @default.
• W2149286249 hasAuthorship W2149286249A5081220639 @default.
• W2149286249 hasAuthorship W2149286249A5086231738 @default.
• W2149286249 hasConcept C111113717 @default.
• W2149286249 hasConcept C112705442 @default.
• W2149286249 hasConcept C121608353 @default.
• W2149286249 hasConcept C124490489 @default.
• W2149286249 hasConcept C126322002 @default.
• W2149286249 hasConcept C134018914 @default.
• W2149286249 hasConcept C185592680 @default.
• W2149286249 hasConcept C22979827 @default.
• W2149286249 hasConcept C2776079296 @default.
• W2149286249 hasConcept C2777288759 @default.
• W2149286249 hasConcept C2778820342 @default.
• W2149286249 hasConcept C2779438470 @default.
• W2149286249 hasConcept C2780580887 @default.
• W2149286249 hasConcept C55493867 @default.
• W2149286249 hasConcept C62478195 @default.
• W2149286249 hasConcept C71924100 @default.
• W2149286249 hasConcept C75217442 @default.
• W2149286249 hasConcept C98274493 @default.
• W2149286249 hasConceptScore W2149286249C111113717 @default.
• W2149286249 hasConceptScore W2149286249C112705442 @default.
• W2149286249 hasConceptScore W2149286249C121608353 @default.
• W2149286249 hasConceptScore W2149286249C124490489 @default.
• W2149286249 hasConceptScore W2149286249C126322002 @default.
• W2149286249 hasConceptScore W2149286249C134018914 @default.
• W2149286249 hasConceptScore W2149286249C185592680 @default.
• W2149286249 hasConceptScore W2149286249C22979827 @default.
• W2149286249 hasConceptScore W2149286249C2776079296 @default.
• W2149286249 hasConceptScore W2149286249C2777288759 @default.

• next